The short answer
Four things to know before the detail.
- No label lists PCOS. Wegovy®, Zepbound® and Foundayo™ are approved for weight reduction in certain people; Mounjaro®, Ozempic® and Rybelsus® are approved for type 2 diabetes. PCOS is not an approved use on any of them.
- Birth control notes differ by medicine. The Mounjaro®, Zepbound® and Foundayo™ labels say these medicines may make birth control pills less effective for a time, and the semaglutide labels carry a note about stopping before a planned pregnancy.
- Tracking makes slow change visible. Weight, symptoms, energy and cycle notes change slowly and unevenly, and a steady log turns weeks of small shifts into something you can discuss.
- Your prescriber makes the call. Whether any medicine fits your situation, and which one, is a medical decision. Bring your questions and your log to that conversation.
What each label is approved for
The approval question is the one most people ask first. This is what each current label lists, in plain words. The weight-reduction and blood-sugar uses are approved alongside diet and physical activity.
| Medicine | Ingredient and form | Approved uses on the label | Boxed warning | Label revised |
|---|---|---|---|---|
| Wegovy® | Semaglutide, weekly injection or daily tablet | Reducing excess body weight in adults with obesity, or overweight plus at least one weight-related condition (the injection also in children 12 and older with obesity); lowering the risk of major heart events in adults with heart disease and obesity or overweight; the injection also for a type of fatty liver disease (MASH) with liver scarring in adults | Risk of thyroid C-cell tumors | 06/2026 |
| Zepbound® | Tirzepatide, weekly injection | Reducing excess body weight in adults with obesity, or overweight plus at least one weight-related condition; moderate to severe obstructive sleep apnea in adults with obesity | Risk of thyroid C-cell tumors | 08/2026 |
| Mounjaro® | Tirzepatide, weekly injection | Blood sugar control in type 2 diabetes (adults and children 10 and older); lowering the risk of major heart events in adults with type 2 diabetes at high risk | Risk of thyroid C-cell tumors | 08/2026 |
| Ozempic® | Semaglutide, weekly injection | Blood sugar control in adults with type 2 diabetes; lowering the risk of major heart events in adults with type 2 diabetes and heart disease; lowering the risk of kidney decline, kidney failure and heart-related death in adults with type 2 diabetes and chronic kidney disease | Risk of thyroid C-cell tumors | 05/2026 |
| Rybelsus® and Ozempic® tablets | Semaglutide, daily tablet | Blood sugar control in adults with type 2 diabetes; lowering the risk of major heart events in adults with type 2 diabetes at high risk | Risk of thyroid C-cell tumors | 01/2026 |
| Foundayo™ | Orforglipron, daily tablet | Reducing excess body weight in adults with obesity, or overweight plus at least one weight-related condition | Risk of thyroid C-cell tumors | 07/2026 |
Where does PCOS fit?
PCOS is not named as an approved use on any of these labels. If a prescriber suggests one of them, it is fair to ask which approved use applies to you, what the other options are, and what the plan is if your goals change.
What is the boxed warning on these labels?
Every label on this page opens with a boxed warning, the FDA's most prominent kind, about the risk of thyroid C-cell tumors. GLP-1 medicines caused these tumors in rats and mice, and it is not known whether they cause them in people, including a thyroid cancer called medullary thyroid carcinoma (MTC). The Foundayo™ label notes that orforglipron is not active in rodents and did not cause tumors in them, and it carries the same boxed warning.
All six labels say not to use the medicine if you or a family member has had MTC, or if you have a condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The Medication Guides tell patients to contact their healthcare provider about a lump or swelling in the neck, hoarseness, trouble swallowing or shortness of breath.
What studies have looked at in PCOS
Researchers have tested GLP-1 medicines in women with PCOS, mostly in small randomized trials. Study results are not an approval: none of the labels lists PCOS, and the studies below do not show that any GLP-1 is right for any one person.
What did a 2019 review compare?
A 2019 review in Reproductive BioMedicine Online pooled eight randomized trials that compared GLP-1 medicines with metformin in women with PCOS. It reported larger changes in insulin sensitivity, BMI and waist size with GLP-1 medicines, and more nausea and headache. On the other measures it compared, which included menstrual cycle and sex hormones, it found no significant difference from metformin. The authors called the evidence inconclusive because of its moderate to low quality, and asked for better trials.
What did a 2024 review compare?
A 2024 review in the Journal of Diabetes and Its Complications pooled four randomized trials with 176 women who had PCOS and obesity, comparing a GLP-1 medicine with placebo. Most participants took liraglutide and a smaller group took semaglutide. It reported lower BMI, waist size, triglycerides and total testosterone, and no clear difference in total cholesterol or in a common measure of insulin resistance (HOMA-IR). Of the 112 women with side-effect data, 49 reported mild effects such as nausea and abdominal pain.
What can these studies not tell you?
Both reviews rest on a small number of trials, and most participants in the 2024 review took liraglutide, which is not one of the six medicines on this page. They cannot tell you whether a GLP-1 is a fit for you or what to expect from one. That is a conversation for your prescriber, who knows your history.
Birth control and pregnancy notes on the labels
Birth control and pregnancy plans are often part of life with PCOS. These are the label statements, quoted as closely as plain English allows, with the label named each time.
Birth control pills and tirzepatide (Mounjaro®, Zepbound®)
The Mounjaro® and Zepbound® labels say tirzepatide may reduce how well birth control pills work, because it slows stomach emptying, and that this delay is largest after the first dose and lessens over time. They advise people using oral hormonal birth control to switch to a non-oral method, or add a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase. Hormonal birth control that is not taken by mouth should not be affected, the labels say.
Birth control and Foundayo™
The Foundayo™ label asks women who could become pregnant to use effective birth control during treatment. Because slower stomach emptying may affect how pills are absorbed, it advises people using oral hormonal birth control to switch to a non-oral method, or add a barrier method, for 30 days after starting and for 30 days after each dose increase.
Planning a pregnancy on semaglutide (Wegovy®, Ozempic®, Rybelsus®)
The Wegovy®, Ozempic®, and Rybelsus® and Ozempic® tablets labels say to stop the medicine at least 2 months before a planned pregnancy, because semaglutide stays in the body a long time. The tirzepatide and Foundayo™ labels do not set a similar stopping window, so ask your prescriber about timing well ahead of any plans.
If a pregnancy happens
The Wegovy®, Zepbound® and Foundayo™ labels say weight loss offers no benefit during pregnancy and may cause harm to the baby. Zepbound® and Foundayo™ say to stop once a pregnancy is recognized, and Wegovy® says to stop it in pregnant patients using it for weight reduction or heart-risk reduction. The Mounjaro®, Ozempic®, and Rybelsus® and Ozempic® tablets labels, written for type 2 diabetes, say the medicine should be used in pregnancy only if the potential benefit justifies the potential risk to the baby. Whichever you take, contact your prescriber right away.
Other medicines taken by mouth
The labels note that slower stomach emptying may affect how other medicines taken by mouth are absorbed. Give your prescriber a full list of everything you take, including birth control, supplements and anything prescribed for PCOS.
What to track when PCOS is part of the picture
Tracking is the practical help you can act on today. Each item below gives you something specific to record and share at your next visit.
Weight as a weekly trend
Day-to-day weight swings for many reasons, which can feel discouraging. Looking at the direction over weeks and months gives a fairer picture than any single morning.
Cycle and symptom notes
Note period timing, skin changes or anything new you notice, with the date and how strong it felt. Those notes give your prescriber something concrete to look at.
Energy, mood and sleep
A quick daily check-in on energy, mood and sleep can help show whether a hard week lines up with a dose change, a busy schedule or something else. Patterns are easier to spot when the check-in is a habit.
Protein, fiber and water
Smaller appetites can leave protein, fiber and fluids short. Keeping an eye on all three is a simple way to notice the gap early.
From the makers of this guide
How Pep AI keeps your week in one place
Pep AI is a tracking app, not a medical device. It keeps your doses, symptoms, weight and meals in one app, so you are not juggling a notes app, a calendar and a spreadsheet.
- 01
Log each shot or pill
Log your GLP-1 doses on the schedule your prescriber set, with shot-day reminders. On iPhone (iOS 17 and later), log in one tap from the Lock Screen Live Activity or the large home screen widget. A body map on Home shows your injection sites from the last 4 weeks so you can rotate them.
- 02
Record symptoms with a severity rating
Choose from a built-in list of symptoms, or add your own, such as a cycle change. Each is rated and dated, and you can add a note for the day. A daily check-in asks about your energy, mood and how you slept.
- 03
Follow weight and progress photos
Your weight history and progress photos sit in one place. Weight can sync with Apple Health on iPhone or Health Connect on Android.
- 04
Protein, fiber and water
Log food by photo scan, barcode, menu scan, search, recent foods or quick log, and track protein, fiber and water against your daily goals.
Questions to bring to your prescriber
The aim of this page is a better appointment, not a decision made on your own. These questions keep every medical choice with your prescriber.
- Is a GLP-1 a fit for me? Which approved use on the label applies to me, what are the other options, and what is the plan if it is not a good fit?
- How does it fit with what I already take? Bring a full list of medicines and supplements, including birth control, and let your prescriber decide whether anything needs to change.
- What about my family plans? If pregnancy is possible now or later, say so early. The labels have specific notes on birth control and on stopping before a planned pregnancy.
- What should I report between visits? Ask which symptoms mean a call and which can wait, and write the answer down.
Bring the record to your appointment
A log is most useful in the exam room. Pep AI builds a PDF report of your doses, injection sites, weight and daily meal totals, which you can share from your phone before or during a visit.
For the most common side effects and what the labels say about them, read the GLP-1 side effects guide. To log them day by day, see the side effects tracker.
If your cycle, temperature or energy feels different since starting, the guide to period changes, hot flashes and fatigue on a GLP-1 covers how to log it and when to call your prescriber. For logging meals with protein and fiber first, see the GLP-1 food tracker.
Key takeaways
- No GLP-1 medication is FDA-approved to treat PCOS; none of the six labels on this page lists it as an approved use.
- Small trials and reviews have looked at GLP-1 medicines in PCOS; their authors describe the evidence as limited, and results are not an approval.
- Mounjaro® and Zepbound® may make birth control pills less effective: the labels advise a non-oral or added barrier method for 4 weeks after starting and after each dose increase. Foundayo™'s label says 30 days.
- The semaglutide labels say to stop at least 2 months before a planned pregnancy. If a pregnancy happens, contact your prescriber right away.
- Every label carries a boxed warning about thyroid C-cell tumors. A dated log of doses, symptoms, cycle notes and weight makes the conversation with your prescriber easier.
Keep your record in one place.
Pep AI logs your doses, symptoms, weight and meals, and makes a PDF of your doses, weight and meal totals. Free to try on iPhone and Android.
Frequently asked questions
Keep reading
Sources
- Wegovy® (semaglutide) injection and tablets prescribing information and Medication Guide, Novo Nordisk / FDA (revised 06/2026)
- Zepbound® (tirzepatide) prescribing information and Medication Guide, Eli Lilly / FDA (revised 08/2026)
- Mounjaro® (tirzepatide) prescribing information, Eli Lilly / FDA (revised 08/2026)
- Ozempic® (semaglutide) injection prescribing information and Medication Guide, Novo Nordisk / FDA (revised 05/2026)
- Rybelsus® and Ozempic® tablets (semaglutide) prescribing information, Novo Nordisk / FDA (revised 01/2026)
- Foundayo™ (orforglipron) prescribing information, Eli Lilly / FDA (revised 07/2026)
- Han Y, Li Y, He B. GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis. Reprod Biomed Online 2019
- Austregésilo de Athayde De Hollanda Morais B et al. The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: a meta-analysis of randomized controlled trials. J Diabetes Complications 2024
This guide is general information based on FDA prescribing information and published research. No GLP-1 medication is FDA-approved to treat PCOS. Pep AI does not recommend any medicine, any dose, or any use that is not on a medicine's label. It is not medical advice and does not replace your prescriber, gynecologist or pharmacist, and Pep AI is not affiliated with Novo Nordisk or Eli Lilly. If a symptom is severe, getting worse, or worrying you, contact your healthcare provider. In an emergency, call 911.
Published by the Pep AI team · Updated November 2026